CTOs on the Move

Jeiven Pharmaceutical Consulting

www.jeiven.com

 
Jeiven Pharmaceutical Consulting is a Scotch Plains, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.jeiven.com
  • 6 Jacobs Ln
    Scotch Plains, NJ USA 07076
  • Phone: 908.233.4508

Executives

Name Title Contact Details

Similar Companies

PioneerRx

PioneerRx is a Shreveport, LA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Commonwealth Biotechnologies

Commonwealth Biotechnologies is a Richmond, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

PharmaLink

PharmaLink is a Largo, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Novo Nordisk

Headquartered in Denmark, Novo Nordisk has more than 5,000 employees in the United States – representing 16% of the total workforce. From our insulin product manufacturing facility in Clayton, , North Carolina, to our Research and Development Center in Seattle, Washington we bring value to communities across the country in a variety of ways.   Our newly constructed LEED-certified building in Plainsboro, New Jersey, is modeled on principles of functionality, innovation, openness, quality, and aesthetics-offering a space that promotes collaboration and creativity.

Ripple Therapeutics

The Ripple Therapeutics Epidel® technology is founded on a discovery that drugs can be engineered into controlled release materials without the use of polymers or excipients. The proprietary prodrugs are new chemical entities (NCEs) that have unique properties that allow them to be processed into standalone drug delivery implants (e.g. intravitreal implants, micro/nanoparticles, etc.) or as coatings on medical devices. Ripple Therapeutics implants and coatings are made up entirely from the prodrug without a polymeric carrier to control the implant or drug release properties. The implants and coatings undergo surface erosion to give zero order drug release profiles and are highly engineerable (e.g. different forms, shapes, and sizes) to tailor drug dose and duration for the specific indication of interest. The flexibility in molecular design results in drug doses that are within the therapeutic window, delivering the right amount of drug for the right amount of time. This has the potential to improve patient safety and clinical outcomes.